&w=1200&q=75)
Innovative SMArT Platform Enhances Gene Editing Safety and Precision in Blood Stem Cells
New 'SMArT' platform makes gene editing in hematopoietic stem cells more efficient and safer
Phys.org
Image: Phys.org
Researchers at the San Raffaele Telethon Institute for Gene Therapy have developed the SMArT platform, which improves CRISPR-Cas9 gene editing in hematopoietic stem cells. This method enhances precision and safety by ensuring targeted gene integration while eliminating harmful genomic alterations, paving the way for broader clinical applications in treating genetic disorders.
- 01The SMArT platform allows for 100% purity in edited hematopoietic stem cells by verifying intended gene integration.
- 02Developed by a team led by Luigi Naldini, the platform addresses safety concerns related to unintended genomic alterations during CRISPR-Cas9 editing.
- 03Three configurations of SMArT function as transient synthetic 'AND-gate' systems to enrich correctly edited cells.
- 04The technology shows promise for treating severe inherited immune disorders like X-linked severe combined immunodeficiency (SCID-X1).
- 05SMArT could be integrated with various gene editing technologies beyond CRISPR-Cas9, enhancing the overall therapeutic potential.
Advertisement
In-Article Ad
A team of researchers from the San Raffaele Telethon Institute for Gene Therapy, led by Luigi Naldini, has introduced the SMArT platform, a significant advancement in CRISPR-Cas9 gene editing for hematopoietic stem cells. Published in *Nature Biotechnology*, this innovative strategy enhances both the precision and safety of gene editing by ensuring targeted integration of gene-sized cassettes while eliminating cells with unintended genomic alterations. SMArT achieves this through a unique selection process that purifies edited cells to near 100% purity. The platform employs a transient synthetic 'AND-gate' system that activates a selectable marker only in cells that have undergone correct editing, thus reducing the risk of harmful outcomes. The study primarily focuses on gene editing for severe inherited immune disorders, such as X-linked severe combined immunodeficiency (SCID-X1), but the researchers believe its applications could extend to various gene editing technologies and disease areas. This approach aims to address critical safety concerns while maximizing the therapeutic potential of gene editing.
Advertisement
In-Article Ad
The SMArT platform could revolutionize gene therapy for blood disorders, improving treatment outcomes and safety for patients with genetic conditions.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of the SMArT platform in gene therapy?
Connecting to poll...
Read the original article
Visit the source for the complete story.